Lataa...
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ(25‐35)‐induced anxiety and cognitive deficits in a mouse model
AIMS: Recently, histone deacetylase (HDAC) inhibitors are considered a possible therapeutic strategy in Alzheimer's disease (AD). However, HDACi treatments exhibit diverse functions with unfavorable effects in AD. Thus, the development of selective HDACi without side effects is urgently needed....
Tallennettuna:
| Julkaisussa: | CNS Neurosci Ther |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488906/ https://ncbi.nlm.nih.gov/pubmed/29978554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13029 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|